Immediate MDoutlook Oncology Intelligence: Surge in the Use of Targeted Agents for Pancreatic Neuroendocrine Tumors Expected in 2011

February 15th, 2011

Last Thursday, two articles in the New England Journal of Medicine described exciting results with sunitinib (Sutent®) and everolimus (Afinitor®) from phase III clinical trials in pancreatic neuroendocrine tumors (PNET). To gauge the immediate impact these reports could have with the global oncology community, MDoutlook launched a global Quick Poll™ of its medical oncology members. Based on the initial results collected over the weekend:

• While 40-50% of oncologists are already using sunitinib or everolimus for the treatment of some of their patients with PNET, over 80% plan on using them in 2011
• The amount of patients with PNET who will receive sunitinib or everolimus for treatment in 2011 is predicted to expand by 2.5-3.0 fold over current levels (see figure below)
• Three quarters of oncologists expect their PNET patients will stay on extended therapy with these agents regardless of the potential for serious side effects
• Usage of these agents in PNET will have little to no effect on their use in metastatic renal cell carcinoma (where both currently have FDA-approval).

MDoutlook PNET Survey 2011: Current and future use of sunitinib and everolimus

MDoutlook is a unique web-based, disease intelligence platform that provides a comprehensive view of clinical decision patterns and treatment choices. Guided by ThoughtLeader composed-strategy councils, MDoutlook offers:
• Treatment Decision Reports and Analysis
• Real-time Chart Pulls with Treatment Decision Rationale
• Current profiles of 50,000 oncologists and their institutions
• ThoughtLeader Influence Mapping and Referral Mapping, as revealed directly by clinicians

For more information about MDoutlook or to receive a final copy of this report when it is available next week, please email [email protected] or call +1.404.496.4136.